137 related articles for article (PubMed ID: 37539500)
1. CP-GEP (Merlin) gene expression profiling: can my melanoma patient forgo sentinel lymph node biopsy?
Quattrocchi E; Meves ES; Meves A
Ital J Dermatol Venerol; 2023 Aug; 158(4):292-301. PubMed ID: 37539500
[TBL] [Abstract][Full Text] [Related]
2. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary.
Johansson I; Tempel D; Dwarkasing JT; Rentroia-Pacheco B; Mattsson J; Ny L; Olofsson Bagge R
Eur J Surg Oncol; 2022 Feb; 48(2):320-325. PubMed ID: 34794843
[TBL] [Abstract][Full Text] [Related]
3. Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy.
Kött J; Zimmermann N; Zell T; Rünger A; Heidrich I; Geidel G; Smit DJ; Hansen I; Abeck F; Schadendorf D; Eggermont A; Puig S; Hauschild A; Gebhardt C
Eur J Cancer; 2024 May; 202():113989. PubMed ID: 38518535
[TBL] [Abstract][Full Text] [Related]
4. Breslow thickness 2.0: Why gene expression profiling is a step toward better patient selection for sentinel lymph node biopsies.
Sadurní MB; Meves A
Mod Pathol; 2022 Nov; 35(11):1509-1514. PubMed ID: 35654998
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: A multicenter prospective Dutch study.
Stassen RC; Mulder EEAP; Mooyaart AL; Francken AB; van der Hage J; Aarts MJB; van der Veldt AAM; Verhoef C; Grünhagen DJ
Eur J Surg Oncol; 2023 Dec; 49(12):107249. PubMed ID: 37907016
[TBL] [Abstract][Full Text] [Related]
6. Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study.
Yousaf A; Tjien-Fooh FJ; Rentroia-Pacheco B; Quattrocchi E; Kobic A; Tempel D; Kolodney M; Meves A
Int J Dermatol; 2021 Jul; 60(7):851-856. PubMed ID: 33914348
[TBL] [Abstract][Full Text] [Related]
7. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.
Mulder EEAP; Dwarkasing JT; Tempel D; van der Spek A; Bosman L; Verver D; Mooyaart AL; van der Veldt AAM; Verhoef C; Nijsten TEC; Grunhagen DJ; Hollestein LM
Br J Dermatol; 2021 May; 184(5):944-951. PubMed ID: 32844403
[TBL] [Abstract][Full Text] [Related]
8. Utility of a Model for Predicting the Risk of Sentinel Lymph Node Metastasis in Patients With Cutaneous Melanoma.
Marchetti MA; Dusza SW; Bartlett EK
JAMA Dermatol; 2022 Jun; 158(6):680-683. PubMed ID: 35475908
[TBL] [Abstract][Full Text] [Related]
9. The Integrated i31-GEP Test Outperforms the MSKCC Nomogram at Predicting SLN Status in Melanoma Patients.
Tassavor M; Martin BJ; Glazer AM
Anticancer Res; 2023 Oct; 43(10):4511-4516. PubMed ID: 37772588
[TBL] [Abstract][Full Text] [Related]
10. Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction.
Whitman ED; Koshenkov VP; Gastman BR; Lewis D; Hsueh EC; Pak H; Trezona TP; Davidson RS; McPhee M; Guenther JM; Toomey P; Smith FO; Beitsch PD; Lewis JM; Ward A; Young SE; Shah PK; Quick AP; Martin BJ; Zolochevska O; Covington KR; Monzon FA; Goldberg MS; Cook RW; Fleming MD; Hyams DM; Vetto JT
JCO Precis Oncol; 2021; 5():. PubMed ID: 34568719
[TBL] [Abstract][Full Text] [Related]
11. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
[TBL] [Abstract][Full Text] [Related]
12. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
Amaral T; Sinnberg T; Chatziioannou E; Niessner H; Leiter U; Keim U; Forschner A; Dwarkasing J; Tjien-Fooh F; Wever R; Flatz L; Eggermont A; Forchhammer S
Eur J Cancer; 2023 Mar; 182():155-162. PubMed ID: 36739215
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
Grossman D; Okwundu N; Bartlett EK; Marchetti MA; Othus M; Coit DG; Hartman RI; Leachman SA; Berry EG; Korde L; Lee SJ; Bar-Eli M; Berwick M; Bowles T; Buchbinder EI; Burton EM; Chu EY; Curiel-Lewandrowski C; Curtis JA; Daud A; Deacon DC; Ferris LK; Gershenwald JE; Grossmann KF; Hu-Lieskovan S; Hyngstrom J; Jeter JM; Judson-Torres RL; Kendra KL; Kim CC; Kirkwood JM; Lawson DH; Leming PD; Long GV; Marghoob AA; Mehnert JM; Ming ME; Nelson KC; Polsky D; Scolyer RA; Smith EA; Sondak VK; Stark MS; Stein JA; Thompson JA; Thompson JF; Venna SS; Wei ML; Swetter SM
JAMA Dermatol; 2020 Sep; 156(9):1004-1011. PubMed ID: 32725204
[TBL] [Abstract][Full Text] [Related]
14. Using the Merlin assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study.
Hieken TJ; Sadurní MB; Quattrocchi E; Kobic A; Sominidi-Damodaran S; Dwarkasing JT; Meerstein-Kessel L; Bridges AG; Meves A
Int J Dermatol; 2022 Jul; 61(7):848-854. PubMed ID: 35100440
[TBL] [Abstract][Full Text] [Related]
15. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.
Han D; Zager JS; Shyr Y; Chen H; Berry LD; Iyengar S; Djulbegovic M; Weber JL; Marzban SS; Sondak VK; Messina JL; Vetto JT; White RL; Pockaj B; Mozzillo N; Charney KJ; Avisar E; Krouse R; Kashani-Sabet M; Leong SP
J Clin Oncol; 2013 Dec; 31(35):4387-93. PubMed ID: 24190111
[TBL] [Abstract][Full Text] [Related]
17. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.
Wong SL; Faries MB; Kennedy EB; Agarwala SS; Akhurst TJ; Ariyan C; Balch CM; Berman BS; Cochran A; Delman KA; Gorman M; Kirkwood JM; Moncrieff MD; Zager JS; Lyman GH
J Clin Oncol; 2018 Feb; 36(4):399-413. PubMed ID: 29232171
[TBL] [Abstract][Full Text] [Related]
18. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Eggermont AM
Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
[TBL] [Abstract][Full Text] [Related]
20. Unique Genes in Tumor-Positive Sentinel Lymph Nodes Associated with Nonsentinel Lymph Node Metastases in Melanoma.
Egger ME; Xiao D; Hao H; Kimbrough CW; Pan J; Rai SN; Cambon AC; Waigel SJ; Zacharias W; McMasters KM
Ann Surg Oncol; 2018 May; 25(5):1296-1303. PubMed ID: 29497912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]